JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flameng, W.
Right arrow Articles by Suy, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flameng, W.
Right arrow Articles by Suy, R.

The Journal of Thoracic and Cardiovascular Surgery, Vol 85, 758-768, Copyright © 1983 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Cardioprotective effects of lidoflazine in extensive aorta-coronary bypass grafting

W Flameng, M Borgers, GJ Van der Vusse, R Demeyere, E Vandermeersch, F Thone and R Suy

The cardioprotective effects of lidoflazine, a calcium entry blocker, were tested in patients undergoing multiple aorta-coronary bypass grafting (at least four grafts). Intermittent aortic cross-clamping at 25 degrees to 28 degrees C was used. Mean cross-clamp time was 11 minutes for one distal anastomosis. Patients were randomized into three groups: a control group (I), a group (II) pretreated with 0.5 mg . kg-1 lidoflazine intravenously before cardiopulmonary bypass (CPB), and a group (III) pretreated with 1 mg . kg-1 lidoflazine intravenously. The following markers of ischemia are used: (1) adenosine triphosphate (ATP), creatine phosphate (CP) and glycogen determined in transmural left ventricular biopsy specimens taken at the beginning and end of CPB; (2) ultrastructure in a similar pair of specimens; and (3) hemodynamic recovery 15 minutes after cessation of CPB. At the end of the intervention, ATP decreased to 73% in Group I but remained unchanged in Groups II (98%) and III (88%). CP decreased to 82% in Group I and remained unaltered in Groups II (100%) and III (110%). Glycogen decreased in Group I (to 44%) and in Group II (78%) but remained unchanged in Group II (138%). Ultrastructural study showed better preservation of the glycocalyx and sarcolemma in Group III than in Group I. Left ventricular stroke work index remained unaltered after CPB in Group III but decreased in Groups I and II to about 60% of its initial value. Thus lidoflazine pretreatment protects the myocardium in a dose-dependent manner against deterioration of myocardial function and structure.


This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
P. Sergeant, P. Wouters, B. Meyns, C. Bert, J. Van Hemelrijck, C. Bogaerts, G. Sergeant, and K. Slabbaert
OPCAB versus early mortality and morbidity: an issue between clinical relevance and statistical significance
Eur. J. Cardiothorac. Surg., May 1, 2004; 25(5): 779 - 785.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
E. R. Rosenkranz
Substrate Enhancement of Cardioplegic Solution: Experimental Studies and Clinical Evaluation
Ann. Thorac. Surg., September 1, 1995; 60(3): 797 - 800.
[Abstract] [Full Text]

Home page
 PerfusionHome page
C. Munsch
Review article : Blood cardioplegia
Perfusion, October 1, 1991; 6(4): 245 - 252.
[PDF]

Home page
 PerfusionHome page
G. Noera, C. Massini, and G. Baggio
In vitro plasma nifedipine concentration during heart-lung machine function
Perfusion, October 1, 1987; 2(4): 277 - 281.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1983 by The American Association for Thoracic Surgery.